Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

Date
2014
Author
Karabulut, Senem
Tas, Faruk
Sen, Fatma
Ciftci, Rumeysa
Duranyildiz, Derya
Disci, Rian
Sakar, Burak
Metadata
Show full item record
Abstract
Serum LDH, CEA, and CA19-9 levels are important tumor markers in pancreatic cancer. The purpose of this study was to evaluate the clinical significance of serum LDH, CEA, and CA19-9 levels in metastatic pancreatic cancer (MPC) receiving gemcitabine-based chemotherapy.
URI
http://hdl.handle.net/20.500.12627/106849
https://doi.org/10.1007/s00280-014-2450-8
Collections